Hints and tips:
Related Special Reports
...Speaking at the company’s headquarters in Bagsværd on the outskirts of Copenhagen, chief executive Lars Fruergaard Jørgensen said potential targets for acquisitions or partnerships included biotech companies...
...Miels said that the pharmaceutical company has since “rebuilt” its business in China....
...The practice is currently limited to a small number of companies, including Illumina and Allelica, and its use is not yet widespread....
...“China is more important to AstraZeneca than [to] other large pharmaceuticals,” said the consultant....
...Enhertu, the first drug from the partnership, brought in $261mn in 2023 and is under regulatory review for a series of different cancer treatments....
...It already made its diagnostics products in the country but had “limited manufacturing for pharma”, he added....
...AstraZeneca already has expertise in RSV, as the drugmaker sells an antibody that protects infants from the disease in partnership with Sanofi. It also markets a nasal flu vaccine....
...Developing new antibiotics is often unattractive for pharmaceutical companies, as research and development costs are high but their use is designed to be limited to reduce the risk of the product driving...
...The partnership adds to a flurry of agreements between big pharmaceutical companies and young AI businesses to build novel disease treatments and cut the costs of developing them....
...To be fair, vaccines have not fallen off the radar: as well as the government’s 10-year partnership with Moderna, AstraZeneca pledged last week to invest £650mn across its Liverpool and Cambridge sites,...
...The push into prescriptions and drug delivery is unusual for a pharmaceutical manufacturer, pitting Eli Lilly against pharmacies such as CVS and Walgreens....
...AstraZeneca has become the latest large pharmaceutical company to sue the US over a law that allows the government to negotiate some drug prices for the first time....
...Many biotechs hoping to enter the market will aim for partnerships with larger groups, a well-trodden path in the pharmaceutical industry....
...Pascal Soriot, AstraZeneca’s chief executive, toured China earlier this year and returned excited about the potential for investing in Chinese biotech, including through acquisitions and partnerships....
...The two diseases targeted by the AstraZeneca agreement are type-1 diabetes and inflammatory bowel disease....
...The same is expected of rival AstraZeneca. The UK-listed business extended further into rare diseases in late July when it bought Pfizer’s early-stage gene therapy portfolio for up to $1bn....
...The writer is executive director of the Global Antibiotic Research & Development Partnership Cancer survival rates have never been higher, but nor have the costs of treating cancer, with the escalating...
...“This partnership is consistent with our focus on products with a high and durable level of differentiation,” he said....
...pill after a partnership deal with Chinese biotech Eccogene....
...as the largest overseas pharmaceutical company by sales....
...According to Dealogic, the outlay by Novo Nordisk and Eli Lilly compares to a total of $305mn that the entire pharmaceutical industry spent on acquisitions and partnerships in the field in the previous ten...
...AstraZeneca is the largest foreign pharmaceutical company by sales in China....
...“As more big pharmaceutical companies show interest [in our work], we will make the AACR event an occasion to sign global partnerships.”...
...Cepi, a partnership set up in 2017 between governments, charities and industry, has taken on a critical role since the Covid-19 pandemic....
International Edition